Pressmeddelanden, rapporter och bolagsmeddelande för Curasight

Lars Trolle, som är vice ordförande i styrelsen, har sålt 50,000 aktier till ett pris av 226,210.10 DKK. Efter försäljningen har han totalt 591,510 aktier i Curasight A/S. För mer information om Curasight kan man kontakta företagets VD, Ulrich Krasilnikoff.

Curasight's CEO, Ulrich Krasilnikoff, reported that in the second quarter of 2025, the company secured approximately DKK 65 million through new capital and loans. This funding will support their theranostic approach using radiopharmaceuticals to improve cancer diagnosis and treatment. The financial boost will help advance their phase II trial for the uTRACE® diagnostic platform in prostate cancer and the phase I trial for uTREAT® in glioblastoma, which has received regulatory approval to begin. For Q2 2025, Curasight reported a gross loss of kDKK -17,700, an operating loss of kDKK -19,011, a loss before tax of kDKK -20,579, and a loss for the period of kDKK -19,204. Total assets were kDKK 44,783, with an equity ratio of 67.6%, and earnings per share of DKK -0.43. For the first half of 2025, the gross loss was kDKK -22,399, operating loss was kDKK -25,220, loss before tax was kDKK -27,158, and loss for the period was kDKK -24,408. Total assets remained at kDKK 44,783, with an equity ratio of 67.6%, and earnings per share of DKK -0.54. These figures are compared to the same period in 2024, shown in parentheses. For further information, contact Ulrich Krasilnikoff.

Curasight is advancing its theranostic strategy for cancer diagnosis and treatment with a Phase 1 trial expected to start dosing patients by the end of the year. The company is now in clinical development with both its diagnostic platform, uTRACE, and therapeutic platform, uTREAT. The trial will explore uTREAT as a targeted radiopharmaceutical therapy for glioblastoma patients, informed by previous research and expert discussions. Curasight's uPAR platform, combining uTRACE and uTREAT, aims to improve diagnosis and treatment of uPAR-expressing cancers. Glioblastoma, a high-grade glioma, has a poor prognosis with a high unmet medical need for effective treatments. uTREAT could potentially reduce reliance on external beam radiation, minimizing side effects by targeting tumor tissue more specifically.

Under perioden 4-18 juni 2025 kunde innehavare av TO3 teckna en ny aktie i Curasight för DKK 15,55 per aktie. Totalt utnyttjades 3 501 teckningsoptioner, vilket motsvarar en teckningsgrad på cirka 0,19 procent. Curasight kommer att få cirka DKK 54 440,6 före avdrag för transaktionskostnader. Omvandlingen från interimsaktier till ordinarie aktier förväntas ske omkring 2 juli 2025. Antalet aktier i bolaget ökar med 3 501 och aktiekapitalet ökar med DKK 175,05, vilket ger en utspädningseffekt på cirka 0,01 procent. Efter registreringen av de nya aktierna kommer det totala antalet aktier i Curasight att vara 45 867 511 och aktiekapitalet DKK 2 293 375,55. Sedermera Corporate Finance AB är finansiell rådgivare, DLA Piper är juridisk rådgivare, och Danske Bank är avvecklingsagent.

Curasight har meddelat att de har lämnat in en ansökan via Clinical Trials Information System (CTIS) för att påbörja en fas 1-studie av uTREAT, en ny typ av riktad strålbehandling för patienter med glioblastom, en aggressiv form av hjärncancer. Studien syftar till att undersöka säkerheten och effektiviteten hos uTREAT. Curasight hoppas att uTREAT kan bli en banbrytande behandling för denna cancerform, som har en mycket dålig prognos och där det finns ett stort medicinskt behov av nya behandlingar. Curasight har också utvecklat uTRACE, en teknik för känslig bilddiagnostik, som tillsammans med uTREAT utgör en integrerad plattform för att förbättra diagnos och behandling av cancer som uttrycker uPAR-receptorn. Glioblastom och andra höggradiga gliom har en mycket låg överlevnadsgrad, och det finns ett stort behov av nya, effektiva behandlingar.

Curasight is required by its articles of association to execute the TO3 warrants at a minimum price of DKK 15.55, which is above the current market price. The board does not expect these warrants to be exercised. In September 2024, Curasight issued 1,841,907 TO3 warrants through a rights issue and a directed issue. Each warrant allows the holder to subscribe for one new share between 4 June 2025 and 18 June 2025, at a price of DKK 15.55 per share. If fully utilized, this would raise approximately DKK 28.6 million before costs, increase the share count to 47,705,917, and raise the share capital by DKK 92,095.35, resulting in a dilution of about 3.9%. Key dates include the start of the exercise period on 4 June 2025, the last trading day on 16 June 2025, the end of the exercise period on 18 June 2025, publication of the outcome on 23 June 2025, and the change from interim shares to shares on 2 July 2025. Sedermera Corporate Finance AB, DLA Piper, and Danske Bank are advising Curasight on this process.

In connection with the Rights Issue, it was announced that guarantee commitments totaling approximately DKK 19.3 million were involved. Guarantors could receive a 13% cash compensation or 22% in newly issued shares. Those opting for cash compensation will receive about DKK 1.36 million. The Directed Issue deviates from shareholders' preferential rights to meet contractual obligations to guarantors. The Board sees issuing new shares as beneficial for the company's financial position. The Directed Issue was authorized at an Extraordinary General Meeting on April 23, 2025, with a subscription price of DKK 1.98 per share, set through negotiations. Payment will offset guarantee claims. The Directed Issue increases share capital by DKK 48,888.40, raising the total number of shares by 977,768 to 45,864,010, resulting in a 2.1% dilution. Sedermera Corporate Finance AB is the Sole Global Coordinator, with DLA Piper as legal advisor and Danske Bank A/S as settlement agent. For more information, contact Sedermera Corporate Finance AB or Ulrich Krasilnikoff, CEO of Curasight A/S.

The registration of new shares from the Rights Issue has been completed with the Danish Business Authority. A total of 23,737,362 shares were subscribed, including a guarantee subscription, increasing the company's share capital by DKK 1,186,868.10. Curasight's share capital now totals DKK 2,244,312.10, equivalent to 44,886,242 shares, with each share valued at DKK 0.05. The new shares are expected to begin trading on June 6, 2025, and convert to ordinary shares by June 10, 2025. Sedermera Corporate Finance AB is the global coordinator and bookrunner, DLA Piper is the legal advisor, and Danske Bank A/S is the settlement agent. For more information, contact Sedermera Corporate Finance AB or Ulrich Krasilnikoff, CEO of Curasight A/S.

At Curasight's Annual General Meeting, several resolutions were passed. The shareholders reviewed and approved the Board of Directors' report on the company's activities and the annual report for 2024. The decision was made to carry forward the profit for 2024 to the next year. The existing board members were re-elected, including Kirsten Aarup Drejer as chairman and Lars Trolle as vice-chairman. PricewaterhouseCoopers was re-elected as the auditor. A proposal to authorize the issuance of up to 7,100,000 warrants for directors, executives, and key employees was approved, with the authorization valid until May 28, 2030. Additionally, the chairman of the meeting, Ulrik Bangsbo Hansen, was authorized to register these resolutions. The updated articles of association and meeting minutes will be available on the company's website.

Curasight's CEO, Ulrich Krasilnikoff, expressed satisfaction with the company's ability to secure new capital amid challenging market conditions, enabling the continued development of cancer treatment options uTRACE® and uTREAT®. The company welcomed new strategic shareholders, Curium and Pentwater, and aims to focus on key clinical milestones, including the completion of a Phase II study on prostate cancer and the initiation of a Phase I study on aggressive brain cancer. The Rights Issue concluded with approximately 47% of shares subscribed, involving 23,737,362 shares, with guarantors covering the shortfall. The company's share capital increased, leading to a 52.9% dilution. Krasilnikoff and Andreas Kjær saw changes in their ownership percentages, while Curium and Pentwater became significant shareholders. No interim share trading will occur, and Sedermera Corporate Finance AB, DLA Piper, and Danske Bank A/S are involved as advisors. The announcement includes legal disclaimers and notes potential risks in forward-looking statements.